TargetMol

Zebularine

Product Code:
 
TAR-T2169
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2169-5mg5mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2169-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2169-10mg10mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2169-25mg25mg£183.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2169-50mg50mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2169-100mg100mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Zebularine is a DNA methylation inhibitor. Acts as a transition state analog inhibitor of cytidine deaminase by binding to the active size as covalent hydrates. It also inhibits cytidine deaminase (Ki: 2 μM, in a cell-free assay).
CAS:
3690-10-6
Formula:
C9H12N2O5
Molecular Weight:
228.2
Pathway:
Autophagy; Chromatin/Epigenetic
Purity:
0.9904
SMILES:
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O
Target:
DNA Methyltransferase; Autophagy

References

1. Zhou L, et al. J Mol Biol, 2002, 321(4), 591-599. 2. Lemaire M, et al. Cancer Chemother Pharmacol, 2009, 63(3), 411-416. 3. Cheng JC, et al. J Natl Cancer Inst, 2003, 95(5), 399-409. 4. Cheng JC, et al. Cancer Cell, 2004, 6(2), 151-158.